IL-23
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Dr. John Cush RheumNow
4 years ago
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more...
https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T


Dr. John Cush RheumNow
4 years ago
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)
Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021.
https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?
Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA.

Dr. John Cush RheumNow
4 years ago
#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow.
https://t.co/sut3zubcow https://t.co/f7XDuRyLB9


Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Dr. John Cush RheumNow
4 years ago
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu


Dr. Rachel Tate uptoTate
4 years ago
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW

Aurelie Najm AurelieRheumo
4 years ago
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI.
#OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM


Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
2021 GRAPPA STRONG recs (cont'd):
*⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
🚫strong rec against IL17i
2021 GRAPPA CONDITIONAL recs for:
*⃣ Uveitis: TNFi (not ETN), CyA
*⃣ Crohn's Dz & UC: IL23i, JAKi, MTX
OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG


Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU


Robert B Chao, MD doctorRBC
4 years ago
Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
⭐️ACR20, 50,70 response
⭐️significant resolution of enthesitis/dactylitis
Abs#OP0228
#EULAR2021 @RheumNow